Results 21 to 30 of about 2,301 (144)
Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control. [PDF]
Cancer Rep (Hoboken)ABSTRACT Background Hematologic disorders, including sickle cell disease, anemias, hemoglobinopathies, leukemias, lymphomas, and bleeding disorders, constitute a substantial and growing burden of morbidity and mortality across Africa. Structural health system constraints—limited diagnostic capacity, shortages of trained hematology specialists ...
Obeagu EI.
europepmc +2 more sources
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Frontiers in Immunology, 2022 Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei +3 more
doaj +1 more source
Next generation of multispecific antibody engineering
Antibody Therapeutics, 2023 Abstract Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with single targeting such as with monoclonal antibodies or cytokines alone.
Daniel Keri +4 more
openaire +2 more sources
Human monoclonal antibodies and monoclonal antibody multispecificity [PDF]
British Journal of Cancer, 1987 The majority of human anti-tumour monoclonal antibodies (Mabs) isolated to date have been disappointing. Firstly, they react or cross react with intracellular cytoskeletal proteins or nuclear antigens and therefore are of limited value as blood borne agents.
A M, Campbell, P, Whitford, R E, Leake
openaire +2 more sources
Biomedicines, 2023 Monoclonal antibody-based therapy has shown efficacy against cancer, autoimmune, infectious, and inflammatory diseases. Multispecific antibodies (MsAbs), including trispecifics (tsAbs), offer enhanced therapeutic potential by targeting different epitopes.
Maria João Sebastião +7 more
doaj +1 more source
Emerging new therapeutic antibody derivatives for cancer treatment
Signal Transduction and Targeted Therapy, 2022 Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin +7 more
doaj +1 more source
mAbs, 2021 Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka +2 more
doaj +1 more source
Computational and Structural Biotechnology Journal, 2020 Multispecific antibodies can be generated in different formats. More than two decades of R&D in the field of bispecific antibody engineering revealed that the design and choice of format can have a profound impact on the antibody functionality.
Steffen Dickopf +2 more
doaj +1 more source
VERITAS: Harnessing the power of nomenclature in biologic discovery
mAbs, 2023 We are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision.
Riti Biswas +6 more
doaj +1 more source
Multispecificity of a recombinant anti‐ras monoclonal antibody [PDF]
Journal of Molecular Recognition, 2017 AbstractRecombinant monoclonal antibodies (Ab's) have widespread application as research tools, diagnostic reagents and as biotherapeutics. Whilst studying the cellular molecular switch protein m‐ras, a recombinant monoclonal antibody to m‐ras was generated for use as a research tool. Antibody genes from a single rabbit B cell secreting IgG to an m‐ras
John W. Schrader, Gary R. McLean
openaire +4 more sources